November 18, 2026
Health news, explained with evidence
LIVE

MD Anderson Study Links IL-18 Protein to Pancreatic Cancer Progression

🧠 AI Analysis 2 min read 👁 2

Researchers have identified that the IL-18 protein helps pancreatic tumors evade the immune system, offering a potential new target for combination therapies.

MD Anderson Study Links IL-18 Protein to Pancreatic Cancer Progression🧠AI Analysis

Photo: Medical Xpress

Key points

  • IL-18 protein helps pancreatic tumors hide from immune cells by boosting CD47 signals.
  • Reducing IL-18 levels in laboratory models slowed tumor growth and improved survival rates.
  • Suppressing IL-18 may enhance the effectiveness of KRAS-targeted therapies and prevent drug resistance.

A research team at The University of Texas MD Anderson Cancer Center has identified a specific inflammatory protein, IL-18, as a key driver in the growth and immune evasion of pancreatic cancer. The study, led by Dr. Yang Chen and Dr. Xinlei Sun, suggests that this protein plays a central role in helping tumors remain undetected by the body's natural defenses, which contributes significantly to disease progression and lower survival rates.

The Mechanism of Immune Evasion

The findings, published in the journal Gastroenterology, demonstrate that IL-18 increases the levels of CD47, a protein known as a "don't eat me" signal. This signal effectively prevents macrophages—immune cells that typically destroy harmful cells—from identifying and attacking the tumor. In preclinical models, reducing the presence of IL-18 allowed macrophages to better recognize and eliminate cancer cells, leading to slower tumor growth and extended survival.

Synergy with Existing Treatments

The study also explored the interaction between IL-18 and KRAS inhibitors, a common class of drugs used to treat pancreatic cancer. Researchers observed that KRAS inhibition can actually cause IL-18 levels to rise, which may help the tumor survive the treatment. However, when the researchers combined KRAS inhibitors with the suppression of IL-18 in lab models, the anti-tumor response was significantly improved, suggesting a potential strategy for overcoming drug resistance.

While these results are promising, it is important to note that the research is currently in the preclinical stage. The study utilized genetically engineered laboratory models rather than human subjects, and further clinical trials are necessary to determine the safety and efficacy of IL-18-targeted therapies in patients. Scientists must still identify how to safely combine these treatments with existing medical protocols.

What to know: This research identifies a new biological pathway that could eventually lead to more effective combination treatments for pancreatic cancer.

Note: Readers should consult with a medical professional before making any decisions regarding cancer treatment or clinical trial participation.

Source Medical Xpress — medicalxpress.com/news/2026-11-key-immune-driver-pancreatic-cancer.html ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.